期刊文献+

粘蛋白MUC1、MUC2在胆囊癌中的联合表达和意义 被引量:1

Expression and significance of MUC1 and MUC2 in primary carcinoma of the gall bladder
下载PDF
导出
摘要 目的探讨MUC1、MUC2在原发性胆囊癌组织中的表达及其在胆囊癌诊断和免疫治疗中的意义。方法采用免疫组化方法检测42例原发性胆囊癌组织和17例正常胆囊组织中MUC1、MUC2的表达。结果MUC1﹑MUC2在胆囊癌组织中的阳性表达率分别为76.19%和47.62%;明显高于正常胆囊组织(29.41%)(P=0.001)和11.76%(P=0.010)。MUC1、MUC2在胆囊癌组织中的阳性表达率与正常胆囊组织之间存在统计学差异(P<0.05)。MUC1、MUC2在胆囊癌组织中阳性表达率与胆囊癌组织病理类型、组织学分化、淋巴结转移及Nevin分期也有相关关系。但与有无合并胆囊结石无相关关系。结论MUC1、MUC2可作为胆囊癌患者预后评价指标,有可能作为肿瘤微转移的诊断及免疫治疗的靶抗原。 Objective To investigate the expression of MUC1 and MUC2 in primary carcinoma of the gall bladder (PCG) and its clinical significance in the diagnosis and immunotherapy of PCG. Methods The expression of MUC1 and MUC2 were examined by immunothistochemical analysis in 42 samples of primary carcinoma of the gall bladder(PCG) and 17 samples of normal gall bladder tissues. Results Immunothistochemical analysis showed that the positive rate of MUC1 and MUC2 in PCG was 76.19% and 47.62%,much higher than that in normal gall bladder tissues(29.41%and ll.76%),The expression levels of MUC1 and MUC2 in PCG was significandy higher than that in normal gall bladder tissues (P〈0.05).expression levels of MUC1 and MUC2 in PCG had statistically correlation with pathological types , differentiation ,lymph node status and Nevin staging. But the expression of MUC1 and MUC2 was not related to the gallstone. Conclusion Over-expression and localization of MUC1 and MUC2 in primary carcinoma of the gall bladder may act as distinguishing diagnostic markers of PCG, and also might be as the target of immunotherapy of PCG.
出处 《海南医学》 CAS 2008年第7期13-14,31,共3页 Hainan Medical Journal
关键词 胆囊癌 粘蛋白 MUC1 MUC2 免疫组化 PCG Mucin MUC1 MUC2 Immunothistochemical
  • 相关文献

参考文献9

  • 1Joo Y E, Park CS. Kim HS, et al. Prognostic significance of E-Cad-herin/Catenin expression in Gastric Cancer[J], J Korean Med Sci,2000,15:655-666.
  • 2石景森,杨毅军,赵凤林,王作仁,周连锁,王林,王健生,何平,卢云,孙立江,焦兴元,刘绍诰.原发性胆囊癌44年诊治的临床回顾[J].外科理论与实践,2001,6(3):137-141. 被引量:47
  • 3王立顺,朱迅.MUC1和MUC2 mRNA在不同肿瘤组织的表达及其意义[J].中国肿瘤临床,2000,27(4):258-261. 被引量:29
  • 4Fujita K, Denda K, Yamamoto M, et al. Expression of MUCI mucins inversely correlated with post-surgical survival of renal cell carcinoma patient[J]. Br J Cancer,1999,80(1):301-308.
  • 5Kawamoto T, Shoda J, et al. Expression of MUCI recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis, 2004,21(4):353-62.
  • 6Yamato T, Sasaki M, Watanahe Y, et al. Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma: an immunohiztochemical and in situ hybridization study. J Pathol,1999,188(1):30-7.
  • 7Ghosh M, Kamma H, Kawamoto T, et al. MUC I core protein as a marker of gallhbladder malignancy. Eur J Surg Oncol,2005,31(8):891-6.
  • 8陈瑞川,林岚,邱达泰,苏金华,吴艳环.RT-PCR扩增MUC1检测胃癌微转移研究[J].福建医科大学学报,1999,33(3):244-247. 被引量:7
  • 9Snijdewint FG, yon Mensdorff-Pouilly S ,Karuntu-Wanamarta AH, et al, Antiboby-dependent cell- mediated cytotoxicity can be induced by MUC1 peptide vaccination of breas: cancer patients [J]. Int J Cancer,2001,93(1 ):97-106.

二级参考文献12

共引文献77

同被引文献61

  • 1谢绍建,闫庆辉,单保恩,付泽娴,孟繁杰,李保东,蔡建辉.转染自体胃癌细胞总RNA的树突状细胞诱导个体化免疫治疗的体外实验[J].细胞与分子免疫学杂志,2006,22(1):92-95. 被引量:14
  • 2魏玲,易艳萍,刘萱,DONALD KUFE,曹诚.MUC1及其C端活性片段突变体具有抑制肿瘤的活性[J].生物化学与生物物理进展,2007,34(4):375-381. 被引量:2
  • 3Gendler SJ, SPicer AP. Epithelial mucin genes[J]. Annu Rev Plant Physiol, 1995,57 : 607 - 634.
  • 4Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface[J]. Nat Rev Cancer,2004,4(1) :45 - 60.
  • 5Muller - Loennies S, Lindner B, Brade H. Structural analysis of oligosaccharides from lipopolysaccharide (LPS) of Escheriehia coli K12 strain W3100 reveals a link between inner and outer core LPS biosynthesis [J ]. J Biol Chem, 2003,278 (36) : 34090 - 34101.
  • 6Vos HL, de Vries Y, Hilkens J. The mouse episialin (Mucl) gene and its promoter., rapid evolution of the repetitive domain in the protein[-J]. Biochem BioPhys Res Commun, 1991,181 (1) : 121 - 130.
  • 7Longenecker BM, Maclean G. Prospects for mucin ePitoPes in cancer vaccines[J]. Clin Trends, 1993, 1:89-93.
  • 8David V Gold, Guy Newsome, Donglin Liu, et al. MaPPing PAM4 (elivatuzumab), a monoclonal an- tibody in clinical trials for early detection and thera- Py of Pancreatic duetal adenocareinoma, to MUC5AC muein [J]. Molecular Cancer, 2013, 12 : 143.
  • 9Tin Wui Wong, Gaia Colombo, Fabio Sonvico. Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment[J]. AAPS Pharm Sci Teeh,2011, 12(1) :201 - 214.
  • 10Hauber HP,Foley SC, Hamid Q. Mucin overproduction in chronic inflammatory lung disease[J]. Can Res Pir J,2006,13(6) :327 - 335.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部